OnKure Therapeutics (OKUR) Stock Forecast & Price Target

Compare

429 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OKUR Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

OnKure

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OKUR Stock 12 Month Forecast

Average Price Target

$23.75

▲(490.80% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for OnKure Therapeutics in the last 3 months. The average price target is $23.75 with a high forecast of $30.00 and a low forecast of $17.00. The average price target represents a 490.80% change from the last price of $4.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,4.92,7.010000000000001,9.100000000000001,11.190000000000001,13.280000000000001,15.370000000000003,17.46,19.550000000000004,21.64,23.730000000000004,25.82,27.910000000000004,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,4.43923076923077,6.048461538461539,7.657692307692308,9.266923076923078,10.876153846153848,12.485384615384616,14.094615384615386,15.703846153846156,17.313076923076927,18.922307692307697,20.531538461538467,22.14076923076923,{"y":23.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,3.92,5.01,6.1000000000000005,7.19,8.280000000000001,9.370000000000001,10.46,11.55,12.64,13.73,14.82,15.910000000000002,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$23.75

Lowest Price Target$17.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert Burns

H.C. Wainwright

$34→$27

Buy

571.64%

Upside

Reiterated

03/16/26

OnKure Therapeutics price target lowered to $27 from $34 at H.C. WainwrightOnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright

Soumit Roy

JonesTrading

$17

Buy

322.89%

Upside

Reiterated

03/16/26

OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst

Sam Slutsky

LifeSci Capital

$21

Buy

422.39%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR), OnKure Therapeutics (NASDAQ: OKUR) and Purple Biotech (NASDAQ: PPBT)

Matthew Biegler

Oppenheimer

$30

Buy

646.27%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (NASDAQ: OKUR) and Verano Holdings (Other OTC: VRNO)

Jonathan Miller

Evercore ISI

―

Buy

―

Reiterated

01/26/26

Evercore ISI Keeps Their Buy Rating on OnKure Therapeutics (OKUR)

Andrew Berens

Leerink Partners

$33

Buy

720.90%

Upside

Reiterated

08/13/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert Burns

H.C. Wainwright

$34→$27

Buy

571.64%

Upside

Reiterated

03/16/26

OnKure Therapeutics price target lowered to $27 from $34 at H.C. WainwrightOnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright

Soumit Roy

JonesTrading

$17

Buy

322.89%

Upside

Reiterated

03/16/26

OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst

Sam Slutsky

LifeSci Capital

$21

Buy

422.39%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NASDAQ: NKTR), OnKure Therapeutics (NASDAQ: OKUR) and Purple Biotech (NASDAQ: PPBT)

Matthew Biegler

Oppenheimer

$30

Buy

646.27%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (NASDAQ: OKUR) and Verano Holdings (Other OTC: VRNO)

Jonathan Miller

Evercore ISI

―

Buy

―

Reiterated

01/26/26

Evercore ISI Keeps Their Buy Rating on OnKure Therapeutics (OKUR)

Andrew Berens

Leerink Partners

$33

Buy

720.90%

Upside

Reiterated

08/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering OnKure Therapeutics

3 Months

xxx

Success Rate

4/9 ratings generated profit

Average Return

-12.38%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -12.38% per trade.

1 Year

Soumit RoyJonesTrading

Success Rate

6/9 ratings generated profit

Average Return

+13.92%

reiterated a buy rating 3 days ago

Copying Soumit Roy's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +13.92% per trade.

2 Years

xxx

Success Rate

6/9 ratings generated profit

Average Return

+18.72%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +18.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OKUR Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OKUR has received 6 Buy Ratings, 28 Hold Ratings, and 0 Sell Ratings. OKUR average Analyst price target in the past 3 months is 23.75.

Each month's total comprises the sum of three months' worth of ratings.

OKUR Financial Forecast

OKUR Earnings Forecast

Next quarter’s earnings estimate for OKUR is -$0.85 with a range of -$1.05 to -$0.55. The previous quarter’s EPS was -$0.99. OKUR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year OKUR has Performed in-line its overall industry.

No data currently available

OKUR Sales Forecast

Next quarter’s sales forecast for OKUR is $167.00K with a range of $0.00 to $500.00K. The previous quarter’s sales results were $0.00. OKUR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year OKUR has Performed in-line its overall industry.

OKUR Stock Forecast FAQ

What is OKUR’s average 12-month price target, according to analysts?

Based on analyst ratings, OnKure Therapeutics’s 12-month average price target is 23.75.

What is OKUR’s upside potential, based on the analysts’ average price target?

OnKure Therapeutics has 490.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OKUR a Buy, Sell or Hold?

OnKure Therapeutics has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is OnKure Therapeutics’s price target?

The average price target for OnKure Therapeutics is 23.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $17.00. The average price target represents 490.80% Increase from the current price of $4.02.

What do analysts say about OnKure Therapeutics?

OnKure Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of OKUR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

OnKure Therapeutics (OKUR) Stock Forecast & Price Target

OKUR Analyst Ratings

OKUR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering OnKure Therapeutics

OKUR Analyst Recommendation Trends

OKUR Financial Forecast

OKUR Earnings Forecast

OKUR Sales Forecast

OKUR Stock Forecast FAQ

Detailed List of Analyst Forecasts